Denton bike riders aim to beat rare disease

by DEBBIE DENMON

WFAA

Posted on March 24, 2012 at 10:04 PM

Updated yesterday at 8:57 AM

DENTON Earlier this week, we introduced you to Natalie Newman, a 13-year-old girl with a rare disease.

She's hoping to beat the odds, and her dream is inspiring hundreds of other people many of whom hit the road Saturday in Denton.

The Ride for Ataxia is a rare race for a rare disease; only the second bike ride of its kind in Texas to raise money and offer education about Friedreich's ataxia, or FA.

"It affects balance and coordination," explained Kyle Bryant. "It is the reason I'm in a trike. I've been using a wheelchair full-time for about two years now, and my symptoms onset when I was 17 years old."

Bryant is beating the odds by living past the age of 30. Many with FA die in their 20s due to heart complications caused by the neuromuscular disorder.

Natalie Newman has also experienced severe side effects, but she is inspired by Kyle and the race. "Hopefully I finish it this time," she said.

Read more here:
Denton bike riders aim to beat rare disease

What is autism? The Mayo Clinic provides some answers

Children with autism generally have problems in three crucial areas of development -- social interaction, language and behavior. But because autism symptoms vary greatly, two children with the same diagnosis may act quite differently and have strikingly different skills. In most cases, though, severe autism is marked by a complete inability to communicate or interact with other people.

Some children show signs of autism in early infancy. Other children may develop normally for the first few months or years of life but then suddenly become withdrawn, become aggressive or lose language skills they've already acquired. Each child with autism is likely to have a unique pattern of behavior.

Common symptoms:

Social skills: Fails to respond to his or her name, poor eye contact, seems not to hear you at times, resists cuddling and holding, appears unaware of others' feelings, seems to prefer playing alone.

Language: Starts talking after age 2, loses previously acquired ability to say words or sentences, speaks with an abnormal tone or rhythm -- may use a singsong voice or robot-like speech, can't start a conversation or keep one going, may repeat words or phrases verbatim, but doesn't understand how to use them.

Behavior: Performs repetitive movements, such as rocking, spinning or hand-flapping, develops specific routines or rituals and is disturbed by the slightest change of routine or ritual, constant movement, fascination by parts of an object, such as the spinning wheels of a toy car, may be unusually sensitive to light, sound and touch and yet oblivious to pain.

As they mature, some children with autism become more engaged with others and show less marked disturbances in behavior. Some, usually those with the least severe problems, eventually may lead normal or near-normal lives. Others, however, continue to have difficulty with language or social skills, and the adolescent years can mean a worsening of behavioral problems.

Most children with autism are slow to gain new knowledge or skills, and some have signs of lower than normal intelligence. Other children with autism have normal to high intelligence. These children learn quickly yet have trouble communicating, applying what they know in everyday life and adjusting in social situations. A small number of children with autism are "autistic savants" and have exceptional skills in a specific area, such as art, math or music.

See a doctor if your child:

* Doesn't babble or coo by 12 months.

Originally posted here:
What is autism? The Mayo Clinic provides some answers

Eastday-Autism groups lack staff, funding

The country's fledgling autism organizations are short of professional staff and government support, a survey released on Sunday shows.

More than half of the autism organizations, or rehabilitation centers, covered in the survey in South China were founded by parents of autistic children, and they raised 75 percent of their initial funding on their own, according to the Shenzhen Autism Society and One Foundation charity, which co-organized the survey.

About 91 percent of the operating costs of these groups are paid by the families of autism sufferers, the report said.

The report is part of a larger national report to be released on April 2, which is 5th World Autism Awareness Day.

The national report, the first of its kind in China, is based on 2,092 questionnaires completed by 56 autism organizations, 988 parents of autistic patients, 510 employees of autism organizations and 538 community organizers. Two-thirds of the questionnaires were submitted from South China.

Liao Yanhui, the secretary-general of the Shenzhen Autism Society, said: "Autism treatment in China faces many difficulties, but there is no statistical support in this field. So we started systematic research in 2009 with financial support from One Foundation."

Wang Ming instructs an autistic 3-year-old in Lanzhou, Gansu province. Wang must repeat the same word as many as 1,000 times before the child can pronounce it.

Link:
Eastday-Autism groups lack staff, funding

Autism groups lack staff, funding

The country's fledgling autism organizations are short of professional staff and government support, a survey released on Sunday shows.

More than half of the autism organizations, or rehabilitation centers, covered in the survey in South China were founded by parents of autistic children, and they raised 75 percent of their initial funding on their own, according to the Shenzhen Autism Society and One Foundation charity, which co-organized the survey.

About 91 percent of the operating costs of these groups are paid by the families of autism sufferers, the report said.

The report is part of a larger national report to be released on April 2, which is 5th World Autism Awareness Day.

The national report, the first of its kind in China, is based on 2,092 questionnaires completed by 56 autism organizations, 988 parents of autistic patients, 510 employees of autism organizations and 538 community organizers. Two-thirds of the questionnaires were submitted from South China.

Liao Yanhui, the secretary-general of the Shenzhen Autism Society, said: "Autism treatment in China faces many difficulties, but there is no statistical support in this field. So we started systematic research in 2009 with financial support from One Foundation."

Wang Ming instructs an autistic 3-year-old in Lanzhou, Gansu province. Wang must repeat the same word as many as 1,000 times before the child can pronounce it. [Cao Zhizheng / for China Daily]

Go here to read the rest:
Autism groups lack staff, funding

Autism groups in China lack support

The country's fledgling autism organisations are short of professional staff and government support, a survey released yesterday shows.

More than half of the autism organisations, or rehabilitation centres, covered in the survey in South China were founded by parents of autistic children, and they raised 75 per cent of their initial funding on their own, according to the Shenzhen Autism Society and One Foundation charity, which co-organised the survey.

About 91 per cent of the operating costs of these groups are paid by the families of autism sufferers, the report said.

The report is part of a larger national report to be released on April 2, which is 5th World Autism Awareness Day.

The national report, the first of its kind in China, is based on 2,092 questionnaires completed by 56 autism organisations, 988 parents of autistic patients, 510 employees of autism organisations and 538 community organisers. Two-thirds of the questionnaires were submitted from South China.

Liao Yanhui, the secretary-general of the Shenzhen Autism Society, said: "Autism treatment in China faces many difficulties, but there is no statistical support in this field. So we started systematic research in 2009 with financial support from One Foundation."

She said the survey found that many autism organisations lack government support, professional teachers and therapists. The groups have called for increasing social awareness and support.

The survey also found there is a huge imbalance in resources. Some organisations have more than 100 teachers, while some have only three staff.

Most teachers in such organisations have less than five years of experience in this sector. Many of them do not hold a bachelor's or higher degree in special education.

They have meagre incomes as well - between 2,000 yuan (US$320) and 3,000 yuan a month - with few training opportunities or chances for promotion. Many autism organisations have high staff turnover, according to the report.

Read the original here:
Autism groups in China lack support

Another of the Early Cryonics Pioneers Cryopreserved

The first generation of the modern cryonics community, people who were middle-aged in the 1970s, is benefiting from the technologies and visions that they built. They founded a movement that has sustained itself for four decades in providing steadily improved cryopreservation services through organizations such as Alcor and the Cryonics Institute. The growth that would remake cryonics as from a non-profit community into a for-profit business with a healthy research and development arm has yet to happen, unfortunately, despite the clear need for the ability to preserve the brains and minds of those who will age to death before the advent of working rejuvenation biotechnology. But the present level of success is enough to provide a shot at renewed life in the future for the few who are determined enough and organized enough to take it.

I see that another of the early cryonics pioneers was cryopreserved recently:

Alcor Co-Founder Fred Chamberlain is Cryopreserved

Fred Chamberlain III who, with his wife Linda, incorporated Alcor in 1972, was cryopreserved by Alcor on March 22, 2012. One week earlier, Fred relocated from Florida to a Scottsdale hospice. This allowed us to watch over him and respond immediately when needed. We believe that Fred received an excellent cryopreservation. More details will be released later.

Linda Chamberlain has released a document to announce his cryopreservation and honor him.

Bon Voyage, Fred Chamberlain

Fred Chamberlain was a NASA-JPL electrical engineer working on the Mariner-Jupiter-Saturn mission in 1973 [and] was and is of absolutely critical importance to cryonics. While most people with more than a passing acquaintance with cryonics will associate his importance with the founding of Alcor, that is in reality only a surrogate marker for his deeper importance. Fred came on the scene in cryonics in what was unarguably its darkest hour. It had degenerated into little more than a fraudulent cult in California and, everywhere in the US, it had lost all vestiges of technical and scientific rigor.

When Fred discovered this in his role as Vice President of the Cryonics Society of California (CSC) he not only left CSC and founded Alcor, he and Linda Chamberlain established, for the first time anywhere, the practice of scientific, evidence based cryonics; cryonics based on the scientific method, on documentation of procedures, policies, cryopreservation protocols and rigorous patient case reports. He and Linda mandated not only scientific and technical accountability, but administrative, financial and legal accountability as well.

Until it does become an earnestly growing industry of many competing companies and millions of cryopreservations every year, cryonics can only work - in the sense of providing a good chance at safe preservation until such time as molecular nanotechnology and other advanced medical technologies can rebuilt and revive cryopreserved individuals - if the movement acts as a community. Maintaining the means of brain preservation for the long term is simply a new option in the general category of caring for elders whose bodies are failing them: this is something that well-balanced communities of humans have accomplished for a long time indeed. So provided that the cryonics movement can persevere as an ordinary, standard community of people with shared interests, as it has for the past 40 years, it should offer those who are cryopreserved a good chance of stability and safety for the decades between now and the advent of restorative technologies of the future.

But that growth is still a better option all round. So very many people go to the grave every day, people who might have chosen cryonics or plastination if those were options backed by a large, vocal industry with millions of customers.

Source:
http://www.longevitymeme.org/newsletter/latest_rss_feed.cfm

An Interview With Dmitry Itskov of Russia 2045

The founder of the Russia 2045 initiative is interviewed here: "Dmitry Itskov is the founder of Global Future 2045, which recently held its first conference. The Russian entrepreneur gathered scientists from around the world to discuss many topics that will help achieve one goal: life extension. ... The main idea of the project and my mission is to help people, to eliminate disease and death probably in the future, to overcome the limitations of our body, and to help humanity grow out of the crisis. As for my personal background, I have always been in the IT business, internet technologies. I published a few internet newspapers in Russia, I produce internet TV channel, a kind of blog service, email service, so being in this business I have always been interested in science and technologies that can extend life. Of course, like anybody, I have seen death and diseases in my family, my grandparents have gone, I've always been thinking how can I personally help. I've also been interested in science and I've seen an example of scientists who haven't gone, who are with us, like Stephan Hawking. He can't even move, he can't even normally talk to people, so this experience inspired me, this made me think how can I participate and help people. I decided to launch such an initiative with the help of Russian scientists who I knew like me. What helped me was that talking to them I was pretty sure that if we launched a kind of a big technical project, a big social initiative, if we work together, if we make our thinking global, and if we are able to launch a global network, then there is a very big chance we make our dreams come true. ... [The Avatar initiative] is the main technological project of the initiative which consists of four steps. One is human-like robot controlled by brain-computer interface. ... the second part is about producing life support system for the human brain. ... The third part is reverse engineering for the brain." The fourth step is to replace the biological brain with an artificial system that is more durable and extendable - which is a long way out, but something that has to be accomplished carefully and thoughtfully to be anything other than an expensive form of suicide that happens to leave behind a copy of the original you. Acceptable means include slowly replacing neurons one by one with nanomachinery that replicates their function and data storage whilst interfacing with the remaining brain tissue - but again, this sort of technology is a long way out from where we stand now, and there are many other challenges to be overcome along the way.

Link: http://sciencefiction.com/2012/03/19/exclusive-interview-with-dmitry-itskov-founder-of-global-future-2045/

Source:
http://www.longevitymeme.org/newsletter/latest_rss_feed.cfm

Transdifferentiation to Simplify Generation of Cells to Order

Researchers are slimming down the process of generating specific types of cell to order, turning the multi-step induced pluripotency processes of the last couple of years into a single step: researchers "have succeeded in obtaining somatic stem cells from fully differentiated somatic cells. [Scientists] took skin cells from mice and, using a unique combination of growth factors while ensuring appropriate culturing conditions, have managed to induce the cells' differentiation into neuronal somatic stem cells. ... Our research shows that reprogramming somatic cells does not require passing through a pluripotent stage. Thanks to this new approach, tissue regeneration is becoming a more streamlined - and safer - process. ... One factor in particular, called Brn4, which had never been used before in this type of research, turned out to be a genuine 'captain' who very quickly and efficiently took command of his ship - the skin cell - guiding it in the right direction so that it could be converted into a neuronal somatic stem cell. ... This interconversion turns out to be even more effective if the cells, stimulated by growth factors and exposed to just the right environmental conditions, divide more frequently. ... Gradually, the cells lose their molecular memory that they were once skin cells. ... It seems that even after only a few cycles of cell division the newly produced neuronal somatic stem cells are practically indistinguishable from stem cells normally found in the tissue. ... So far, insights are based on experiments using murine skin cells; the next steps now are to perform the same experiments using actual human cells. In addition, it is imperative that the stem cells' long-term behaviour is thoroughly characterized to determine whether they retain their stability over long periods of time."

Link: http://www.mpg.de/5548755/stem_cells_skin_cells

Source:
http://www.longevitymeme.org/newsletter/latest_rss_feed.cfm

Ongoing Mining of Human Studies for Correlations Between Metabolic Markers and Longevity

A number of research groups have spent the past few years aggressively mining the population of ongoing human longevity studies, taking advantage of the falling cost of biochemical and genetic assays in order to conduct as many tests as they can: the more data the better. This has resulted in a steady stream of papers that report an increasing number of correlations between specific biological markers and longevity in human populations - though as noted in past posts here, these rarely hold up in different study groups, indicating a large number of tiny contributions to longevity, most of which vary greatly in their effects between human lineages. Metabolism is ferociously complex, and the metabolic aspects that determine natural human longevity no less so.

At this point, there is more pouring of data into the hopper and sorting it all into buckets than there is real progress in understanding - that comes later. Here are two recent examples of this sort of research publication:

Cortisol serum levels in familial longevity and perceived age: The Leiden Longevity Study

Cortisol levels are strongly associated with a person's health. Familial longevity and age assessment of facial photographs (perceived age) are both associated with morbidity and mortality. The present study aimed to investigate morning cortisol levels in familial longevity and the association of these levels with perceived age. ... Perceived age and serum morning cortisol levels were measured for 138 offspring from long-lived families and 138 partners from the Leiden Longevity Study. ... This study demonstrates that high levels of cortisol are associated with a higher perceived age. This association was attenuated in offspring from long-lived families compared to their partners, suggesting enhanced stress resistance in these subjects. Future research will be aimed at elucidating potential mechanisms underlying the observations in this study.

Family History of Exceptional Longevity Is Associated with Lower Serum Uric Acid Levels in Ashkenazi Jews

OBJECTIVES: To test whether lower serum uric acid (UA) levels are associated with longevity independent of renal function.

PARTICIPANTS: Long-lived individuals (LLI) of Ashkenazi Jewish ethnicity, their offspring and controls (without family history of longevity).

RESULTS: Offspring were less likely to have hyperuricemia and had lower UA levels than controls. ... Furthermore, significant association between UA levels in LLI and their offspring has been observed.

CONCLUSION: Offspring had lower UA levels than controls despite similar renal function, suggesting that other factors such as UA metabolism or renal tubular transport determine UA levels. The association between UA levels and longevity is particularly intriguing because UA levels are potentially modifiable with diet and drugs.

Interesting as these studies are - when you read through them in connection with the dozens of other correlation studies examining the biochemistry of human longevity - this is really all something of a sideshow. There is no such thing as useless knowledge in the long term, and this all goes towards the final complete understanding of human metabolism that will exist in the future, but it doesn't help us move any faster now towards the goals of engineered longevity. There is an existing, well-defined path towards the production of rejuvenation biotechnology, and that path is where the majority of funding and effort should go if we want to see a real impact on the future trajectory of our own longevity.

Source:
http://www.longevitymeme.org/newsletter/latest_rss_feed.cfm

An Update on Bacterial Aging

The aging of bacteria has been a topic of interest in the years since its discovery; firstly, it overturns the long-held assumption that bacteria are essentially immortal, and secondly it provides insight into the very early evolutionary origins of aging. Here is a recent update: "Evidence for aging in symmetrically dividing bacteria such as Escherichia coli has historically been conflicting. Early work found weak or no evidence. More recent studies found convincing evidence, but negative results are still encountered. Because bacterial aging is believed to result from non-genetic (e.g. oxidative) damage, we tested the possibility that the negative outcomes resulted from the lack of an extrinsic damage agent. We found that streptomycin, which produces mistranslated proteins that are more vulnerable to oxidation, was able to induce both damage and aging in bacterial populations. A dosage effect relating the level of damage to the concentration of streptomycin was observed. Our results explain the previous inconsistencies because all studies that failed to find evidence for bacterial aging did not use a damage agent. However, all studies that succeeded in finding evidence utilized fluorescent proteins as a visual marker. We suggest that aging in those studies was induced by the harmful effects of an extrinsic factor, such as of the proteins themselves or the excitation light. Thus, all of the previous studies can be reconciled and bacterial aging is a real phenomenon. However, the study and observation of bacterial aging requires the addition of an extrinsic damage agent."

Link: http://www.ncbi.nlm.nih.gov/pubmed/22422756

Source:
http://www.longevitymeme.org/newsletter/latest_rss_feed.cfm

Popular Press on Organ Regrowth

A BBC News article: "It might seem unbelievable, but researchers can grow organs in the laboratory. There are patients walking around with body parts which have been designed and built by doctors out of a patient's own cells. ... There is a pressing need. A shortage of available organs means many die on waiting lists and those that get an organ must spend a lifetime on immunosuppressant drugs to avoid rejection. The idea is that using a patient's own stem cells to grow new body parts avoids the whole issue of rejection as well as waiting for a donor. ... Dr Anthony Atala [has] made breakthroughs in building bladders and urethras. He breaks tissue-building into four levels of complexity. 1) Flat structures, such as the skin, are the simplest to engineer as they are generally made up of just the one type of cell. 2) Tubes, such as blood vessels and urethras, which have two types of cells and act as a conduit. 3) Hollow non-tubular organs like the bladder and the stomach, which have more complex structures and functions. 4) Solid organs, such as the kidney, heart and liver, are the most complex to engineer. They are exponentially more complex, have many different cell types, and more challenges in the blood supply. ... We've been able to implant the first three in humans. We don't have any examples yet of solid organs in humans because its much more complex. ... One of the problems when you move to larger organs is the getting the blood supply to work, connecting arteries, capillaries and veins to keep the organ alive. It is why some researchers are investigating 'decellularisation' - taking an existing donated organ, stripping out the original cells and replacing them with new cells from the patient who will receive the organ."

Link: http://www.bbc.co.uk/news/health-16679010

Source:
http://www.longevitymeme.org/newsletter/latest_rss_feed.cfm

Theorizing More Broadly on the Topic of the Evolution of Longevity

The evolution of aging and longevity is a field in which it's still comparatively easy to make a mark and carve out an area of new theory. For most species it is still the case that ideas on their longevity are comparative unsettled: why they live as long as they do, what mechanisms may have determined their life span, and how it all fits in to the bigger picture of metabolism and the evolution of specific biological processes. There is far more data than any one group of researchers could hope to organize in a lifetime, and new information continues to flood in ever faster as the biotechnology revolution unfolds.

At some point this rich wealth of data starts to give rise to hypotheses that are more holistic: evolution as a system of systems linked by feedback loops, thousands of species interacting with one another in any given biome, and the evolution of each species highly connected to that of its peers. Embarking upon this level of modeling and understanding, all the way down to biomolecular processes, will keep evolutionary biologists busy for the next century or so, I'd imagine - and give them something to do with the staggering levels of computing power that will be available by that time.

Here is an interesting open access paper that gives a hint of the shape of this sort of future research, whilst considering the evolution of longevity amongst interacting species:

Various organisms (i.e., bacteria, fungi, plants and animals) within an ecosystem can synthesize and release into the environment certain longevity-extending small molecules. Here we hypothesize that these interspecies chemical signals can create [selective] forces driving the ecosystemic evolution of longevity regulation mechanisms.

In our hypothesis, following their release into the environment by one species of the organisms composing an ecosystem, such small molecules can activate anti-aging processes and/or inhibit pro-aging processes in other species within the ecosystem. The organisms that possess the most effective (as compared to their counterparts of the same species) mechanisms for sensing the chemical signals produced and released by other species and for responding to such signals by undergoing certain hormetic and/or [cellular housekeeping related] life-extending changes to their metabolism and physiology are expected to live longer then their counterparts within the ecosystem.

Thus, the ability of a species of the organisms composing an ecosystem to undergo life-extending metabolic or physiological changes in response [to] chemical compounds released to the ecosystem by other species: 1) increases its chances of survival; 2) creates selective forces aimed at maintaining such ability; and 3) enables the evolution of longevity regulation mechanisms.

So the researchers propose that such things as the ability of rapamycin (produced by soil bacteria) to extend life in mice or the beneficial effects of mammalian bile acid on yeast life span are late manifestations of cross-species evolutionary processes that have been going on since the very earliest epoch of multicellular life. The suggestion is that we should expect there to be a wide range of compounds produced by varied species that will have some beneficial effect on the life span of another species (such as by improving cellular housekeeping processes), because the existence of such relationships between species is a fundamental characteristic of diverse ecosystems produced by evolution.

Which is an interesting line of thought, and I look forward to seeing where it leads.

Source:
http://www.longevitymeme.org/newsletter/latest_rss_feed.cfm

An Outsider's Overview of Cryonics, Part II

The second part of an article in CMAJ that shows off some of the subtle prejudices against cryonics that exist in the medical scientific community (such as in the choice of title) while attempting objectivity: "Although death and taxes are said to be the only two certainties in life, a small but vocal community takes issue with the inclusion of the former. There is, they say, the alternative of cryonics, in which a legally dead person is preserved at -196C in hopes that he will ultimately be revived and rejuvenated, once a cure for his ailment is found. And it's entirely consistent with the basic tenets of medicine, providers argue. ... Although it seems like an unusual and radical idea to many people, I think in the very truest sense of the term, this is conservative medicine. This is literally conserving a patient rather than giving up on them by today's standards of medicine. It's true a doctor can't do anything more for these people, but that doesn't mean the future cannot. ... Those interested in cryonics tend be optimistic, hopeful about technological developments and dissatisfied with an ordinary life span, says Ben Best, president of the Cryonics Institute. ... a miniscule chance is better than none, enthusiasts say. ... Nobody has come up with a better idea yet, so therefore myself, as well as some others, believe that cryonics is simply the second worst thing that can happen. You're going to die. You're going to stop breathing. Whether you be buried or cremated or cryopreserved, it's going to happen. There's nothing we can do about this now, but I know that if I'm cremated or buried, even if technology vastly increased, I'm never coming back. ... Enthusiasts are mystified that only a small segment of the general population has investigated the cryonic option. ... I don't know why there are far more people who don't sign up for cryonics arrangements. It's true that what we do is unorthodox and different, at least in 2012. But there are so many bizarre ideas out there which have no evidence to support them and get many, many people fascinated ... Yet we only have less than 1000 members after 40 years. ... People tend in my experience to kind of rely on this naturalistic [fallacy] that because people have always gotten older and died, therefore they should get older and die as a result of simply living longer."

Link: http://www.cmaj.ca/site/earlyreleases/20mar12_the-church-of-cryopreservation.xhtml

Source:
http://www.longevitymeme.org/newsletter/latest_rss_feed.cfm

An Outsider’s Overview of Cryonics, Part II

The second part of an article in CMAJ that shows off some of the subtle prejudices against cryonics that exist in the medical scientific community (such as in the choice of title) while attempting objectivity: "Although death and taxes are said to be the only two certainties in life, a small but vocal community takes issue with the inclusion of the former. There is, they say, the alternative of cryonics, in which a legally dead person is preserved at -196C in hopes that he will ultimately be revived and rejuvenated, once a cure for his ailment is found. And it's entirely consistent with the basic tenets of medicine, providers argue. ... Although it seems like an unusual and radical idea to many people, I think in the very truest sense of the term, this is conservative medicine. This is literally conserving a patient rather than giving up on them by today's standards of medicine. It's true a doctor can't do anything more for these people, but that doesn't mean the future cannot. ... Those interested in cryonics tend be optimistic, hopeful about technological developments and dissatisfied with an ordinary life span, says Ben Best, president of the Cryonics Institute. ... a miniscule chance is better than none, enthusiasts say. ... Nobody has come up with a better idea yet, so therefore myself, as well as some others, believe that cryonics is simply the second worst thing that can happen. You're going to die. You're going to stop breathing. Whether you be buried or cremated or cryopreserved, it's going to happen. There's nothing we can do about this now, but I know that if I'm cremated or buried, even if technology vastly increased, I'm never coming back. ... Enthusiasts are mystified that only a small segment of the general population has investigated the cryonic option. ... I don't know why there are far more people who don't sign up for cryonics arrangements. It's true that what we do is unorthodox and different, at least in 2012. But there are so many bizarre ideas out there which have no evidence to support them and get many, many people fascinated ... Yet we only have less than 1000 members after 40 years. ... People tend in my experience to kind of rely on this naturalistic [fallacy] that because people have always gotten older and died, therefore they should get older and die as a result of simply living longer."

Link: http://www.cmaj.ca/site/earlyreleases/20mar12_the-church-of-cryopreservation.xhtml

Source:
http://www.longevitymeme.org/newsletter/latest_rss_feed.cfm

Vernor Vinge on Radical Life Extension

From an interview with Vernor Vinge at Wired: "First of all, I'm all for human life extension. In The Singularity is Near, I think, [Ray Kurzweil] has a nice discussion of the situation that a lot of essayists have where they say, 'Oh, we really don't want that. A wise and philosophical person realizes that life needs be limited, and that's a good thing,' these essayists say. He does a good job of criticizing that point of view, and I certainly agree with that. Furthermore, I think that a human lifespan of a thousand years with post-Singularity technology is easily doable. I think a lifespan of a thousand years would actually - Singularity aside - would do human society and human nature a great deal of good, and don't think it is that difficult, it probably can even be achieved without having a Technological Singularity. Life spans of 10,000 to 100,000 years, then you begin to look at what's involved, the humans that are involved, and how capable a human mind is of absorbing variety. ... The complaint or the criticism here is that the human mind has a certain level of ability to handle different sorts of complexity, and if you believe that you could go 100,000 years and not be turned into a repeating tape loop, well, then let's talk about longer period of time. How about a billion years, or a hundred billion years? At a hundred billion years, you're out there re-engineering the universe. The age of the universe becomes your chief longevity problem. But there's still the issue of, what would it be like to be you after that? This raises the point, which actually I'm sure is also on Ray's mind, that if you're going to last that long you have to become something greater, and the Singularity is ideally set up to supply that. So the people who are into the intelligence amplification mode of looking at these things, this all fits. And I'm not saying that in a critical and negative way, it does all fit, and it puts you in a situation where you are talking realistically about living very long periods of time, perhaps so long that you have to re-engineer the universe because the universe is not long-lived enough. At the same time, you have to be growing and growing and growing. I mean, intellectually growing. Now, if you look at that situation, it ultimately gets you, I think, to a very interesting philosophical point, which really I don't think was within the horizon of what people normally thought about two or three or four hundred years ago."

Link: http://www.wired.com/underwire/2012/03/vernor-vinge-geeks-guide-galaxy/

Source:
http://www.longevitymeme.org/newsletter/latest_rss_feed.cfm

SENS5 Video: More on that General Method of Correcting Mitochondrial Mutations

Mitochondria crowd your cells, roving descendants of ancient bacteria that were long ago co-opted to serve as power plants, turning food into adenosine triphosphate (ATP), the energy store chemical used to power cellular machinery. As a legacy of their bacterial origins, mitochondria carry their own DNA, separate from that in the cell nucleus. Making ATP is a messy business, creating all sorts of reactive molecules as byproducts, and that mitochondrial DNA is more vulnerable than the safely enclosed nuclear DNA. The balance of evidence strongly implicates mitochondrial DNA damage as one of the contributing causes of aging. A damaged gene can no longer be used as a blueprint for the process of gene expression that produces the protein machinery that is vital to the operation of a mitochondrion, and from there matters only go downhill - it's a long road that ends up at atherosclerosis, neurodegeneration, and many other forms of advanced age-related degeneration.

Thus finding ways to repair mitochondrial DNA (mtDNA) is of great importance - but this is still a minority field of science in comparison to stem cell medicine or cancer research. Nonetheless, mitochondrial repair has been attracting some attention in the past week, as an important new line of research made it to the press release and publicity stage. The technique demonstrated is not really repair, per se, more a method of working around damage to mitochondrial genes - but it looks to be a great improvement over existing methodologies in terms of cost, time, and difficulty. This may enable broader and faster progress towards therapies that can remove the harm caused by damaged mitochondria. You might peruse these recent posts for more details on the work:

The new method is a way to deliver more or less arbitrary RNA to mitochondria, which should allow for continued function even after mutational damage to important genes. Production of RNA is a first step in the convoluted process of gene expression - by which genes are used as a blueprint for proteins - so it's quite possible to skip the gene and start with the RNA. This shortcut is the basis for a range of modern life science research, and one obvious use is to correct for a missing or damaged gene: find a way to provide the patient with an ongoing supply of suitably crafted RNA molecules targeted to the right places in his or her cells and it won't matter that the gene is broken.

I should note that there are only thirteen genes in the mitochondria that are important for the purposes of this discussion, but the process of producing repairs or workarounds for each one has been hard, very different for each of them, slow, and difficult up until this point. A method that works in a very similar way for all of them is a big deal.

The researchers presented on their work in RNA last year at SENS5, and I see that the SENS Foundation volunteers moved up the presentation video in the queue for processing and posted it to YouTube today:

A decline in the function of mitochondria may contribute to the aging process and age-related disorders. A functional decline could arise from accumulated mtDNA mutations over time, leading to reduced oxidative phosphorylation and other untoward effects on mitochondrial activities. Strategies that restore mitochondrial function could potentially offset key aspects of aging decline. RNA import into mammalian mitochondria is considered essential for replication, transcription, and translation of the mitochondrial genome but the pathway(s) and factors that control this import are poorly understood.

In recent studies we have shown a role for polynucleotide phosphorylase (PNPASE) in regulating the import of nuclear-encoded RNAs into the mitochondrial matrix. ... A mitochondrial RNA targeting signal was identified that enables the import of heterologous RNAs in a PNPASE-dependent manner. Combined, our studies show an unanticipated role for PNPASE in mediating the translocation of RNAs into mitochondria and provide a potential therapeutic route for halting or reversing the decline in mitochondrial function with aging.

In short, the researchers have found a mechanism that can be hijacked in order to import RNA into the mitochondria as desired.

Source:
http://www.longevitymeme.org/newsletter/latest_rss_feed.cfm

Study Reports Progress Against Fatal Brain Cancer

(HealthDay News) -- A new method to prevent recurrence of deadly glioblastoma brain cancer shows promise, say U.S. scientists.

Radiation can temporarily shrink a glioblastoma tumor, but the cancer nearly always recurs within weeks or months. Few people with this type of brain cancer survive more than two years after diagnosis.

In a study on mice, Stanford University School of Medicine researchers found that blocking access to oxygen and nutrients prevents tumor recurrence.

The first step, they said, was discovering that tumors blasted with radiation use a secondary pathway to generate blood vessels needed for regrowth.

"Under normal circumstances, this pathway is not important for growth of most tumors," senior author Martin Brown, a professor of radiology, said in a Stanford news release. "What we hadn't realized until recently is that radiation meant to kill the cancer cells also destroys the existing blood vessels that nourish the tumor. As a result, it has to rely on a backup blood delivery pathway."

The Stanford team used a molecule called AMD3100 to block the secondary glioblastoma tumor growth process in mice.

The study was published online Feb. 22 in the Journal of Clinical Investigation. Read more...

Immunice for Immune Support

Source:
http://feeds.feedburner.com/integratedmedicine

€3m to support skills development in biotechnology sector

€3m to support skills development in biotechnology sector

The new joint venture

Recently, University College Dublin and Elan came out with a big news which is expected to mark a new beginning in the field of biotechnology. Both of these institutions will be working together on a venture. The highlight of this venture would be its cross linking policy between both the students of business studies and science branch in the university. The venture is expected to use the fusion of application of business studies and that of science including biology and applied engineering.

How will the venture work?

The venture is expected to run for at least seven years and will cost the company more than three million euros. The investment in the university’s new science center will help open two new scholarships (post doctoral ones). And that is not all. Another announcement has been made that lectures will now be organized annually, which will be targeted towards the students of the university, helping them to develop their intellectual abilities.

This groundbreaking initiative will not only be targeted towards the development of both biotechnology and the business associated with it but will also be acting as a juncture that will allow the students of science, business management and medical branch to work together under the common umbrella of Elan.

How will it affect the students?

The people in charge in both the organizations say that the venture will benefit the students at more than one level. On one hand, the venture will allow the students of different branch of studies to work together, and on the other hand, it will allow the students to work with the best in their respected fields. It will also allow the students to learn about the ever changing and risky world of bio technology. Although this is a giant leap for those involved, the success of the venture remains to be seen in time.

Source:
http://www.biotechblog.org/rss.xml

Business of biotechnology

Technology that makes use of any kind of living organism, for example, micro organisms, is known as biotechnology. Modern medical science, especially biotechnology, has emerged as a booming profitable business in the last few decades. Perceiving further growth in the sector, venture capitalists have increased their investments in this field. However promising the sector looks, venture capitalists are wary of investing their money in the startup firms owing to the risks involved and doubts about their sustainability.
What the report says?
The national venture capitalist Association and Pricewaterhouse Cooper Ltd. reported that $4.73 billion was spent by venture firms on 446 biotechnology companies in 2011 while only 153 pharmaceutical companies and equipment companies were able to receive their first funding from the venture capitalists, thus making it the lowest since 1996.
The number of new firms that have been registered with Food and Drug Administration has also gone up. The rise is calculated of about 43%. Out of these registered companies, only 13% some of them owe their success to venture capital funds.
This decline in the funding for startup biotech companies would affect the future innovation in this sector because of which we would see less number of innovations in the biotechnology field.
Summary
Venture capitalists are profit driven people. They decide their own rules before investing in a biotech company while entrepreneurs in this field are idea driven. The idea that they might have hit upon during their academic years might take a little longer to translate into commercial success. The perspective with venture capitalists is generally for 10 years or less than that. Therefore, they are averse to funding projects that may require more than 10 years to be a success, which is generally the case with most of these companies. Hence, we see a decline in funding at the outset. But, the need is to be more patient and have faith in the entrepreneur and his idea so that future innovation is not affected.

Source:
http://www.biotechblog.org/rss.xml

Biotechnology industry on the upswing: Aeterna Zentaris and Elite Pharmaceuticals to benefit

Early stages of the year 2012 have resulted into a great beginning for the entire biotechnology industry. This has led to a whooping increase in the NASDAQ Biotechnology index, which is currently 80% higher than before. The industry is recovering really fast from the previous economic crisis. An increase in the funding for the biotech industry has been recently reported by the GIA (Global Industry Analysts). Various investing opportunities in the field of biotechnology, equity researches in the field of Elite Pharmaceuticals and Aeterna Zentaris Inc., have been put forth by the Paragon report.
GIA has come up with a wonderful prediction of a whooping US$320 billion increase in funding for research and development by the year 2015. This includes expansion of this industry in medical sciences as well as agriculture. There are various government initiatives in the pipeline which would help in driving growth in this industry. GIA further explains that various developing industry markets like China and India can emerge as useful industrial and agricultural biotechnology markets, as they have witnessed increase in income levels and population. These countries are developing into a great hub for biotech drugs as they come with a great and rich talent pool and reduced cost of investments. This was recently stated by GIA in a press release. Various oral sustained and controlled drugs and products have already been developed by Elite Pharmaceuticals Inc. The strategy of Elite focuses on bringing in various partner companies in the product management life cycle. This has led to a vast improvement of various off-patent products of drugs. It was only during the last week that Elite announced its initial shipment of the drug methadone hydrochloride (10mg tabs) to one of its wholly owned subsidiary,The Pharma Network, LLC, as well as Ascend Laboratories, LLC. This was done in regards with the commercial manufacturing and supply agreement. Aeterna Zentaris has developed various drugs for oncology researches. It has also proven quite beneficial for investigating treatments for different cancers like multiple myeloma, ovarian, colorectal, bladder and prostrate cancers.

The paragon report for such investigations and upswings in biotechnology has been compensated by various third party organizations for advertising requirements.

Source:
http://www.biotechblog.org/rss.xml